Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)

Launched by MAYO CLINIC · Sep 8, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how people recover from Cushing syndrome (CS) after surgery, particularly focusing on the effects of glucocorticoid withdrawal syndrome (GWS). Cushing syndrome is a condition caused by too much cortisol in the body, often leading to various health issues. After surgery to correct this problem, patients may experience symptoms from suddenly lowering their cortisol levels, known as GWS. The study aims to find out what factors may predict how long and how severe these withdrawal symptoms will be and to see if a specific intervention, called MUSE, can help reduce the severity of these symptoms compared to standard care.

To participate in this trial, individuals must be 18 years or older and have a new diagnosis of Cushing syndrome, including its various forms. They should also be planning for curative surgery and able to provide informed consent. Participants can expect to be closely monitored before and after their surgery to track their recovery and any symptoms they experience. This trial is currently recruiting participants, and it's important for those interested to understand that their involvement could contribute valuable information about managing recovery from this complex condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. age 18 and above,
• • 2. new diagnosis of CS of any of the three subtypes (pituitary, adrenal or ectopic CS), and MACS,
• • 3. planning for a curative surgery
• • 4. ability to provide informed consent.
• Exclusion Criteria:
• • 1. systemic supraphysiological GC for any reason within 1 month of enrollment, for more than 2 weeks,
• • 2. inability to provide informed consent